Business · 20/10/1998Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Aldara Patent Extension
Summary
The FDA has officially set a review period for a patent extension application for Aldara, a human drug product, as required by law, following a submission to the US Patent and Trademarks Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →